Drug Information

Drug General Information
Drug ID
D05LQX
Former ID
DIB015458
Drug Name
BOL-303259-X
Synonyms
Latanoprostene bunod; Latanoprostene bunod); NCX-116; PF-03187207; PF-3187207; BOL-303259-X1; NO donors (glaucoma), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer; Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer; NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb
Drug Type
Small molecular drug
Indication Renal cancer [ICD9: 140-229, 189; ICD10:C64] Phase 3 [524354]
Company
NicOx SA; bausch & lomb
Structure
Download
2D MOL

3D MOL
Formula
C27H41NO8
Canonical SMILES
O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\\C=C/CCCC(=O)O<br />CCCCON(=O)=O)CCc2ccccc2
InChI
1S/C27H41NO8/c29-22(15-14-21-10-4-3-5-11-21)16-17-24-23(25(30)20-26(24)31)12-6-1-2-7-13-27(32)35-18-8-9-19-36-28(33)34/h1,3-6,10-11,22-26,29-31H,2,7-9,12-20H2/b6-1-/t22-,23+,24+,25-,26+/m0/s1
InChIKey
LOVMMUBRQUFEAH-UIEAZXIASA-N
PubChem Compound ID
11156438
Target and Pathway
Target(s) Prostaglandin F2-alpha receptor Target Info Agonist [531388]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Reactome Prostanoid ligand receptors
G alpha (q) signalling events
WikiPathways Prostaglandin Synthesis and Regulation
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Small Ligand GPCRs
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 524354ClinicalTrials.gov (NCT01895972) A Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension. U.S.National Institutes of Health.
Ref 531388Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.